Orphazyme to get rid of two thirds of employees

The recent FDA rejection of Orphazyme's main candidate is now being felt by its employees.
Photo: Nikolaj Skydsgaard/REUTERS / X07081
Photo: Nikolaj Skydsgaard/REUTERS / X07081

Biotech firm Orphazyme reports that it has to cut two thirds of its workforce and bid three of its board members farewell.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading